The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0246 GMT - IHH Healthcare's 10% year-to-date share price decline could offer a potential entry point, with its operations expected to improve across key markets, Kenanga IB analyst Raymond Choo Ping Khoon says in a note. Singapore operations are recovering, with bed occupancy rising above 52% in August and September compared with 51% in 2Q, he says. Performance in Turkey and Europe is also expected to improve in 2H as recent hospital acquisitions ramp up. In India, Gleneagles Healthcare's margins are expected to move closer to Fortis Healthcare's, while Greater China could provide further upside if losses narrow faster than expected, he adds. Kenanga upgrades IHH's rating on outperform from market perform, raises target price to 9.10 ringgit from 8.50 ringgit. Shares are 0.5% higher at 8.04 ringgit. (yingxian.wong@wsj.com)

1038 GMT - Novo Nordisk's capital markets day announcements, including the diversification plan and a vague midterm sales target, disappointed investors, AlphaValue analyst Abhishek Raval writes. "Against the backdrop of excessive dependency on a single molecule, aggressive and heavy diversification bets, along with impeccable commercial execution, are the need of the hour." However, the markets have their reservations, Raval says. The commercial success of oral Wegovy, some promising late-stage assets, and the firepower for acquisitions provide reasons to bet on Novo, which is available at a discount to peers, he adds. AlphaValue rates the Danish drugmaker's stock at buy with a 450 Danish kroner target price. Shares fall 0.2% to 259.40 kroner. (dominic.chopping@wsj.com)

0909 GMT - Novo Nordisk's 8% share price fall following the investor day is an overreaction, but proves that investors remain nervous about 2027, with expected price pressure and CagriSema drug launch skepticism, Berenberg analysts write. The Novo story appears more interesting from 2028, with zenagamtide phase 3 data, CagriSema bone and muscle function data and multiple phase 1 and 2 readouts, the bank says. The event provided a comprehensive overview of the company's strategy, R&D pipeline and business operations, but offered only incremental strategic insights, it adds. The 2030 and 2035 sales ambitions were also outlined, which are broadly in line with expectations. Understanding the need to quickly diversify the portfolio ahead of U.S./EU semaglutide patent expiry early next decade, Novo aims to significantly speed up development and supplement the internal pipeline. Shares fall 0.7%.